Skye Bioscience to Present Poster on Nimacimab at Keystone Obesity Conference
ByAinvest
Wednesday, Jan 21, 2026 7:02 am ET1min read
SKYE--
Skye Bioscience will present a poster at Keystone's Obesity Therapeutics conference, addressing questions about its peripherally-restricted CB1-inhibitor antibody, nimacimab. The poster will explore its potential to enhance weight loss with incretin agonists, durability of weight loss after treatment discontinuation, and use as a maintenance therapy after tirzepatide discontinuation. Nimacimab is a potential first-in-class drug designed to avoid central nervous system penetration and act independently of the GLP-1 pathway.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet